BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The applicant Novartis Europharm Ltd. submitted on 5 October 2006 an application for Marketing 
Authorisation to the European Medicines Agency (EMEA) through the centralised procedure for 
Tasigna, which was designated as an orphan medicinal product EU/3/06/375on 22 May 2006 (CML) 
and EU/3/07/447 on 13 April 2007. Tasigna was designated as an orphan medicinal product in the 
following indications: treatment of chronic myeloid leukaemia and treatment of gastrointestinal 
stromal tumours. The calculated prevalence of those conditions was 2.4 per 100,000 EU population for 
chronic myeloid leukaemia and 4.13 per 100,000 EU population for gastrointestinal stromal tumours. 
The applicant applied for the following indication: 
Treatment of chronic phase and accelerated phase Philadelphia chromosome positive chronic 
myelogenous leukaemia (CML) in adult patients resistant to or intolerant to at least one prior therapy 
including imatinib. 
The legal basis for this application refers to:  
Article 8.3 of Directive 2001/83/EC, as amended - complete and independent application 
The application submitted is a complete dossier: 
composed of administrative information, complete quality data, non-clinical and clinical data based on 
applicants’ own tests and studies and/or bibliographic literature substituting/supporting certain tests or 
studies 
Information relating to Orphan Market Exclusivity 
Similarity 
Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) 
No 847/2000, the application contained a critical report addressing the possible similarity with 
authorised orphan medicinal products 
Market Exclusivity 
Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) 
No 847/2000, the application contained a justification addressing the following derogation laid down 
in Article 8.3 of the same Regulation; the holder of the marketing authorisation for the original orphan 
medicinal product has given his consent to the applicant. 
Scientific Advice: 
The applicant received Scientific Advice from the CHMP on 22 April 2006 and 18 November 2006. 
The Scientific Advice pertained to clinical aspects of the dossier. 
Licensing status: 
A new application was filed in the following countries: U.S.A. 
The product was not licensed in any country at the time of submission of the application. 
The Rapporteur and Co-Rapporteur appointed by the CHMP were: 
Rapporteur: 
Jens Ersbøll (DK) 
Co-Rapporteur 
Harald Enzmann (DE) 
EMEA Product Team Leader: Maria Nieto-Gutierrez 
EMEA 2007 
1/2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2. 
Steps taken for the assessment of the product 
 
 
 
 
 
 
 
 
 
 
 
 
 
The application was received by the EMEA on5 October 2006.  
The procedure started on 25 October 2006. 
The Rapporteur's first Assessment Report was circulated to all CHMP members on 17 January 
2007. The Co-Rapporteur's first Assessment Report was circulated to all CHMP members on 21 
January 2007. 
During  the  meeting  on  19 –  22  February  2007,  the CHMP  agreed  on  the  consolidated  List  of 
Questions to be sent to the applicant. The final consolidated List of Questions was sent to the 
applicant on 22 February 2007. 
The CHMP adopted a report on similarity of Tasigna with Glivec on 22 March 2007. 
The applicant submitted the responses to the CHMP consolidated List of Questions on 12 April 
2007. 
The Rapporteurs circulated the Joint Assessment Report on the applicant’s responses to the List 
of Questions to all CHMP members on 29 May 2007. 
During  the  CHMP  meeting  on  18  –  21  June  2007,  the  CHMP  agreed  on  a  list  of  outstanding 
issues to be addressed in writing or in an oral explanation by the applicant. 
The CHMP adopted a report on similarity of Tasigna with Sprycel on 21 June 2007. 
The applicant submitted the responses to the CHMP consolidated List of Outstanding Issues on 
24 August 2007. 
The Rapporteurs circulated the Joint Assessment Report on the applicant’s responses to the List 
of Outstanding Issues to all CHMP members on 11 September 2007. 
During  the  meeting  on  17  –  20  September  2007,  the  CHMP,  in  the  light  of  the  overall  data 
submitted  and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for 
granting a Marketing Authorisation to Tasigna on 20 September 2007. The applicant provided 
the letter of undertaking on the specific obligations and follow-up measures to be fulfilled post-
authorisation on 19 September 2007. 
The  CHMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission, which adopted the corresponding Decisions on 19 November 2007. 
EMEA 2007 
2/2 
 
 
 
 
 
 
 
